These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 12469940)
21. Comparison of the pharmacokinetics of subcutaneous and intravenous administration of a phosphorothioate oligodeoxynucleotide in cynomolgus monkeys. Leeds JM; Henry SP; Geary R; Burckin T; Levin AA Antisense Nucleic Acid Drug Dev; 2000 Dec; 10(6):435-41. PubMed ID: 11198927 [TBL] [Abstract][Full Text] [Related]
22. Inhibition of coagulation by a phosphorothioate oligonucleotide. Henry SP; Novotny W; Leeds J; Auletta C; Kornbrust DJ Antisense Nucleic Acid Drug Dev; 1997 Oct; 7(5):503-10. PubMed ID: 9361909 [TBL] [Abstract][Full Text] [Related]
29. Effects of human and murine antisense oligonucleotide inhibitors of ICAM-1 on reproductive performance, fetal development, and post-natal development in mice. Henry SP; Denny KH; Templin MV; Yu RZ; Levin AA Birth Defects Res B Dev Reprod Toxicol; 2004 Dec; 71(6):359-67. PubMed ID: 15617021 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotide in monkeys. Monteith DK; Horner MJ; Gillett NA; Butler M; Geary R; Burckin T; Ushiro-Watanabe T; Levin AA Toxicol Pathol; 1999; 27(3):307-17. PubMed ID: 10356707 [TBL] [Abstract][Full Text] [Related]
31. Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma. Yu RZ; Baker B; Chappell A; Geary RS; Cheung E; Levin AA Anal Biochem; 2002 May; 304(1):19-25. PubMed ID: 11969184 [TBL] [Abstract][Full Text] [Related]
32. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Levin AA Biochim Biophys Acta; 1999 Dec; 1489(1):69-84. PubMed ID: 10806998 [No Abstract] [Full Text] [Related]
33. Single-dose hemodynamic toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after intravenous infusion to cynomolgus monkeys. Wallace TL; Bazemore SA; Kornbrust DJ; Cossum PA J Pharmacol Exp Ther; 1996 Sep; 278(3):1306-12. PubMed ID: 8819516 [TBL] [Abstract][Full Text] [Related]
34. Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis. Miner PB; Geary RS; Matson J; Chuang E; Xia S; Baker BF; Wedel MK Aliment Pharmacol Ther; 2006 May; 23(10):1427-34. PubMed ID: 16669957 [TBL] [Abstract][Full Text] [Related]
35. Mechanistic understanding for the greater sensitivity of monkeys to antisense oligonucleotide-mediated complement activation compared with humans. Shen L; Frazer-Abel A; Reynolds PR; Giclas PC; Chappell A; Pangburn MK; Younis H; Henry SP J Pharmacol Exp Ther; 2014 Dec; 351(3):709-17. PubMed ID: 25301170 [TBL] [Abstract][Full Text] [Related]
36. bis-Cholesteryl-conjugated phosphorothioate oligodeoxynucleotides are highly selectively taken up by the liver. Bijsterbosch MK; Manoharan M; Dorland R; Van Veghel R; Biessen EA; Van Berkel TJ J Pharmacol Exp Ther; 2002 Aug; 302(2):619-26. PubMed ID: 12130724 [TBL] [Abstract][Full Text] [Related]
37. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Rudin CM; Holmlund J; Fleming GF; Mani S; Stadler WM; Schumm P; Monia BP; Johnston JF; Geary R; Yu RZ; Kwoh TJ; Dorr FA; Ratain MJ Clin Cancer Res; 2001 May; 7(5):1214-20. PubMed ID: 11350886 [TBL] [Abstract][Full Text] [Related]
38. A nonradioisotope approach to study the in vivo metabolism of phosphorothioate oligonucleotides. Cohen AS; Bourque AJ; Wang BH; Smisek DL; Belenky A Antisense Nucleic Acid Drug Dev; 1997 Feb; 7(1):13-22. PubMed ID: 9055034 [TBL] [Abstract][Full Text] [Related]
39. Distribution and excretion of a phosphorothioate oligonucleotide in rats with experimentally induced renal injury. Masarjian L; de Peyster A; Levin AA; Monteith DK Oligonucleotides; 2004; 14(4):299-310. PubMed ID: 15665597 [TBL] [Abstract][Full Text] [Related]
40. Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). Watanabe TA; Geary RS; Levin AA Oligonucleotides; 2006; 16(2):169-80. PubMed ID: 16764540 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]